Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000009.xml
Am J Perinatol 2024; 41(S 01): e1090
DOI: 10.1055/a-1990-2322
DOI: 10.1055/a-1990-2322
Letter to the Editor
Urinary Terminal Probrain Natriuretic Peptide in Preterm Infants
Funding None.

Key Points
-
POCUS is a dynamic way of assessing cardiopulmonary function.
-
POCUS would be more cost-effective than urine NT-proBNP.
-
Although POCUS is costly as compared with urine NT-proBNP, it is a one-time investment.
Publication History
Received: 27 October 2022
Accepted: 18 November 2022
Accepted Manuscript online:
30 November 2022
Article published online:
16 January 2023
© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Khan SS, Bada HS, Torres M, Almodovar M, Hanna M. The trend of urinary N terminal probrain natriuretic peptide in extremely low birth weight infants during the neonatal period. Am J Perinatol 2022; 39 (10) 1027-1032
- 2 Turnbough L, McKenna A, Manzar S. Simultaneous echocardiogram and N-terminal-probrain natriuretic peptide measurement in neonates. J Biomed Res Environ Sci 2022; 3 (04) 413-418